Xavier Pivot

Summary

Affiliation: CHU Jean Minjoz
Country: France

Publications

  1. ncbi request reprint Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Ann Oncol 12:1595-9. 2001
  2. ncbi request reprint Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer
    X Pivot
    Service d Oncology, CHU J Minjoz, Besancon, France
    Ann Oncol 14:373-7. 2003
  3. pmc Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study
    Aline Voidey
    Department of Pharmacy, Jean Minjoz University Hospital, 2 Boulevard Fleming, 25000 Besancon, France
    BMC Health Serv Res 14:326. 2014
  4. doi request reprint Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment
    Bernard Royer
    UMR645, INSERM, Besancon, France
    Clin Pharmacokinet 48:169-80. 2009
  5. doi request reprint Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer
    Erion Dobi
    Department of Medical Oncology, University Hospital of Besancon, Besancon, France
    Clin Colorectal Cancer 12:28-36. 2013
  6. doi request reprint Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?
    Erion Dobi
    Department of Medical Oncology, University Hospital of Besancon, Besancon, France
    Int J Clin Oncol 18:607-13. 2013
  7. pmc Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis
    Elsa Curtit
    Department of Medical Oncology, University Hospital, Besancon, France
    Oncologist 18:667-74. 2013
  8. doi request reprint 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
    Xavier Pivot
    University Hospital J Minjoz, Besancon, France
    Lancet Oncol 14:741-8. 2013
  9. doi request reprint Cabazitaxel: a novel microtubule inhibitor
    Cristian Villanueva
    Department of Medical Oncology, University Hospital, Besancon, France
    Drugs 71:1251-8. 2011
  10. doi request reprint Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma
    Antoine Thiery-Vuillemin
    Oncologie, Besançon Cedex CIC BT506, CHRU INSERM, UMR1098 UMR1098, Université de Franche Comté EFS Bourgogne Franche Comté Laboratoire de Pharmacologie Clinique et Toxicologie, Besancon, France
    J Immunother 37:51-4. 2014

Detail Information

Publications44

  1. ncbi request reprint Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer
    X Pivot
    Centre Antoine Lacassagne, Nice, France
    Ann Oncol 12:1595-9. 2001
    ..3% and 10.8% of objective responses, 1.9 versus 1.5 months of disease-free progression and 3.5 versus 3.7 months of overall survival, respectively. Nolatrexed has demonstrated a similar activity to methotrexate...
  2. ncbi request reprint Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer
    X Pivot
    Service d Oncology, CHU J Minjoz, Besancon, France
    Ann Oncol 14:373-7. 2003
    ....
  3. pmc Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study
    Aline Voidey
    Department of Pharmacy, Jean Minjoz University Hospital, 2 Boulevard Fleming, 25000 Besancon, France
    BMC Health Serv Res 14:326. 2014
    ..The objective of our study was to assess, using a quality approach, the impact on medical management and on the costs of treating early breast cancer, of the new regional structure for cancer care delivery...
  4. doi request reprint Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment
    Bernard Royer
    UMR645, INSERM, Besancon, France
    Clin Pharmacokinet 48:169-80. 2009
    ..Intraperitoneal (IP) peroperative chemotherapy is an interesting therapeutic option. However, very few data are available regarding pharmacokinetics and especially population pharmacokinetics...
  5. doi request reprint Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer
    Erion Dobi
    Department of Medical Oncology, University Hospital of Besancon, Besancon, France
    Clin Colorectal Cancer 12:28-36. 2013
    ..These results highlight the potential role of STAT3 as a molecular target to optimize anti-EGFR therapies...
  6. doi request reprint Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?
    Erion Dobi
    Department of Medical Oncology, University Hospital of Besancon, Besancon, France
    Int J Clin Oncol 18:607-13. 2013
    ..This study searched for extra capsular tumour spread (ECS) as a prognostic factor for recurrence in terms of Disease Free Survival (DFS) and Overall Survival (OS)...
  7. pmc Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis
    Elsa Curtit
    Department of Medical Oncology, University Hospital, Besancon, France
    Oncologist 18:667-74. 2013
    ..Secondary aims included patients' characteristics, overall survival, feasibility of histopathological evaluation in the metastatic setting, and predictive factors associated with receptors status discordance...
  8. doi request reprint 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
    Xavier Pivot
    University Hospital J Minjoz, Besancon, France
    Lancet Oncol 14:741-8. 2013
    ..However, the optimum duration of treatment has been debated. We did a non-inferiority trial of a shorter exposure of 6 months versus the standard 12 months of trastuzumab for patients with early breast cancer...
  9. doi request reprint Cabazitaxel: a novel microtubule inhibitor
    Cristian Villanueva
    Department of Medical Oncology, University Hospital, Besancon, France
    Drugs 71:1251-8. 2011
    ..This article presents the preliminary antitumour activity, safety, tolerability and pharmacokinetic data of cabazitaxel, and an overview of the current status of clinical development...
  10. doi request reprint Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma
    Antoine Thiery-Vuillemin
    Oncologie, Besançon Cedex CIC BT506, CHRU INSERM, UMR1098 UMR1098, Université de Franche Comté EFS Bourgogne Franche Comté Laboratoire de Pharmacologie Clinique et Toxicologie, Besancon, France
    J Immunother 37:51-4. 2014
    ..Thus, a change of immune functions is associated with everolimus treatment. Our observation suggests that everolimus could shape immune responses, which in turn could contribute to its efficacy. ..
  11. doi request reprint Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions
    Frederic Fiteni
    Department of Medical Oncology, Besancon University Hospital, Besancon, France
    Breast 23:165-9. 2014
    ..The objective of this study was to search for significant prognostic factors in patients with HER2+ MBC treated by trastuzumab taking into account the institution where the treatment was given...
  12. doi request reprint A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies
    Erika Viel
    Department of Medical Oncology, Besancon University Hospital, Besancon, France
    Am J Clin Oncol 31:89-94. 2008
    ....
  13. doi request reprint [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region]
    Virginie Nerich
    CHU de Besancon, Pôle pharmacie, Besancon, France, Inserm U645 EA 2284 IFR 133, Universite de Franche Comte, 25000 Besancon, France
    Bull Cancer 101:681-9. 2014
    ..This strategy was successful and may allow the reimbursement of this test in France for patients with early breast cancer. ..
  14. ncbi request reprint Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury
    Elsa Curtit
    University of Franche Comte, Besancon, France
    Anticancer Res 32:1481-3. 2012
    ..The process applied to extravasations of irritant and non-vesicant agents could be used to manage extravasations of liposomal doxorubicin...
  15. ncbi request reprint Impact of chemotherapy beyond the first line in patients with metastatic breast cancer
    Armelle Dufresne
    Medical Oncology, CHU Minjoz, Bd Fleming, Besancon, France
    Breast Cancer Res Treat 107:275-9. 2008
    ..The goal of this study was to determine which benefit could be brought by the succession of chemotherapy lines in patients treated for metastatic breast cancer and to identify patients who benefit from these treatments...
  16. ncbi request reprint Is there still a role for triple endoscopy as part of staging for head and neck cancer?
    Emmanuel Guardiola
    Department of Oncology, CHU Jean Minjoz, Besancon, France
    Curr Opin Otolaryngol Head Neck Surg 14:85-8. 2006
    ..If these carcinogenic factors can induce the development of a cancer in one of these locations, it would seem reasonable that a second cancer could appear in another of those areas, at the same time or at some point in the future...
  17. doi request reprint [Follow-up in patients with early breast cancer]
    Tristan Maurina
    CHU Jean Minjoz, Service d Oncologie Medicale, Boulevard Fleming, Besancon, France
    Bull Cancer 98:1091-106. 2011
    ..Our study underlines significant disparities among patients follow-up. Better interactions between physicians and a greater implication of patients in their follow-up would increase its quality...
  18. doi request reprint Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Fabien Calcagno
    Department of Medical Oncology, CHRU Minjoz, Besancon, France
    Med Oncol 33:89. 2016
    ..It might offer a new safe and non-expensive option to delay initiation of ADT. These results would need to be confirmed with larger prospective randomised trials. ..
  19. doi request reprint Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer
    Laura Mansi
    EA4267 UFR 33, School of Medecine and Pharmacy Medical Oncology Unit, J Minjoz University Teaching Hospital INSERM U 645, EA 2284 IFR 133 and Department of Surgery and Pharmacy Department, J Minjoz University Hospital, Besancon, France
    Int J Gynecol Cancer 26:261-7. 2016
    ..Secondary objectives were to identify patients who benefited from treatments beyond 3 lines and to estimate overall survival and disease-free progression lengths...
  20. pmc Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer
    Fabien Calcagno
    Centre Hospitalier Universitaire Besançon, Oncology, Besancon, France
    Clin Med Insights Oncol 7:1-12. 2013
    ..This review describes pharmacologic parameters of this agent followed by a review of clinical trials involving cabazitaxel. Other available treatments and the place of cabazitaxel in metastatic CRPC setting are discussed...
  21. doi request reprint First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis
    Virginie Nerich
    Department of Pharmacy, University Teaching Hospital of Besançon, France INSERM U645 EA 2284 IFR 133, University of Franche Comte, Besancon, France
    J Oncol Pharm Pract 20:362-8. 2014
    ..To carry out a cost-minimization analysis including a comparison of the costs arising from first-line treatment by trastuzumab plus docetaxel versus trastuzumab plus paclitaxel in patients with metastatic breast cancer...
  22. doi request reprint Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells
    Romain Bedel
    INSERM Institut National de la Santé et de la Recherche Médicale UMR 645, Besancon, France
    Cancer Res 71:1615-26. 2011
    ..Together, our findings reveal a novel role for STAT3 in NK cell immunosurveillance by modulating the MICA expression in cancer cells...
  23. pmc In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?
    Xavier Pivot
    Departments of Medical Oncology, Gynecology, Pathology, and Statistics, University Hospital Jean Minjoz, Besancon, France University of Franche Comté, UMR1098, SFR IBCT, Besancon, France INSERM, UMR1098, Besancon, France EFS Bourgogne Franche Comté, UMR1098, Besancon, France Genomic Health, Inc, Redwood City, California, USA
    Oncologist 20:344-50. 2015
    ..Tumor size is used as a key parameter when selecting patients for neoadjuvant chemotherapy. The aim of this study was to assess the distribution of RS in patients selected for neoadjuvant chemotherapy primarily according to tumor size...
  24. doi request reprint Ixabepilone: a new active chemotherapy in the treatment of breast cancer
    Cristian Villanueva
    University of Hospital Jean Minjoz, Department of Medical Oncology, Besancon, France
    Womens Health (Lond) 5:115-21. 2009
    ....
  25. ncbi request reprint Ixabepilone, a novel epothilone analog in the treatment of breast cancer
    Xavier Pivot
    Oncologie Médicale, CHU J Minjoz, 25000 Besancon, France
    Expert Opin Investig Drugs 17:593-9. 2008
    ..Ixabepilone (BMS-247550, Ixempra) is an epothilone analog that optimizes the properties naturally observed with epothilone B...
  26. doi request reprint Combining molecular targeted therapies: clinical experience
    Xavier Pivot
    Department of Oncology, University Hospital Jean Minjoz, Besancon, France
    Anticancer Drugs 22:701-10. 2011
    ..Therefore, at this point no general guidance to study such combinations can be derived...
  27. pmc Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
    Frederic Fiteni
    Department of Medical Oncology, University Hospital of Besancon, Besancon, France Methodology and Quality of Life in Oncology Unit, University Hospital of Besancon, Besancon, France
    Cancer Med 3:1502-11. 2014
    ..These results suggest that the Gem/CDDP regimen with cisplatin (25-35 mg/m(2)) administered on days 1 and 8 is associated with survival advantage than Gemox regimen but with addition of toxicity...
  28. ncbi request reprint Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer
    Xavier Pivot
    Department of Medical Oncology, CHU J Minjoz, 25030 Besancon Cedex, France
    Oral Oncol 41:320-7. 2005
    ..Laryngectomy seems to erase the prognostic impact of EGFR expression. These results profile the use of EGFR targeting therapy for this category of patients...
  29. doi request reprint Response rates: a valuable signal of promising activity?
    Xavier Pivot
    Department of Oncology, University Hospital J Minjoz, Besancon, France
    Cancer J 15:361-5. 2009
    ..Although these guidelines for response assessment have limitations and biases, they have nevertheless been proven useful and advantageous. This article reviews those criteria and describes their use...
  30. pmc Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients
    Marie Christine Etienne-Grimaldi
    Centre Antoine Lacassagne, Nice, France
    Br J Clin Pharmacol 71:921-8. 2011
    ..We therefore prospectively tested the impact of these five gene polymorphisms (blood DNA) on the pharmacodynamics of bevacizumab-based treatment administered in metastatic breast cancer patients...
  31. doi request reprint Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06
    C Villanueva
    Centre Hospitalier Universitaire de Besancon, Besancon, France
    Target Oncol 8:137-43. 2013
    ..These preliminary results suggest that the addition of lapatinib to letrozole has a favorable safety profile and could overcome tumoral resistance to letrozole among HER2-negative tumors...
  32. pmc Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation
    Jean R Pallandre
    INSERM U645, EFS Bourgogne Franche Comte, University of Franche Comte, IFR133, Besancon, France
    Blood 112:4420-4. 2008
    ..These findings point to a pivotal role of CX3CL1 in the activation of resting NK cells by mature DCs...
  33. pmc Efficacy of trabectedin in metastatic solitary fibrous tumor
    Loic Chaigneau
    Department of Medical Oncology, Universitary Hospital Center J Minjoz, Besancon, France
    Rare Tumors 3:e29. 2011
    ..5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option...
  34. doi request reprint Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity
    Laurent Beziaud
    INSERM UMR1098, TIMC LabEx LipSTIC, Besancon, France University of Bourgogne Franche Comté, UMR1098, Besancon, France
    Cancer Res 76:4100-12. 2016
    ..Cancer Res; 76(14); 4100-12. ©2016 AACR. ..
  35. doi request reprint Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations
    Xavier Pivot
    aDepartment of Medical Oncology, University Hospital Jean Minjoz, Besançon bFaculty of Pharmacy of Lyon cLéon Bérard Cancer Center, Lyon dGeorge François Leclerc Cancer Center, Dijon eDeparment of Radiotherapy, University Hospital Tenon, Paris fFSNB Health and Care, Paris gDepartment of Pharmacy, University Hospital Jean Minjoz, Besancon, France
    Anticancer Drugs 26:1009-16. 2015
    ..A think tank of experts was created to delineate specificities and challenges stemming from trastuzumab biosimilars. ..
  36. doi request reprint Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
    Xavier Pivot
    CHU Jean Minjoz, Besancon, France
    Lancet Oncol 14:962-70. 2013
    ..We assessed patient preference for either subcutaneous or intravenous trastuzumab in the international, randomised PrefHer study...
  37. ncbi request reprint Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan?
    Emmanuel Guardiola
    Department of Oncology, CHU J Minjoz, Besancon, Cedex, France
    Cancer 101:2028-33. 2004
    ..The objective of the current study was to analyze the results obtained by triple endoscopy during the initial evaluation of a primary carcinoma of the head and neck...
  38. doi request reprint Cost-utility analyses of drug therapies in breast cancer: a systematic review
    Virginie Nerich
    Department of Pharmacy, University Hospital of Besancon, Boulevard Fleming, Besancon, France
    Breast Cancer Res Treat 159:407-24. 2016
    ..That being said, there is an urgent need for mandatory use of European and international recommendations to ensure quality of such approaches and to allow easy comparison. ..
  39. ncbi request reprint Efficacy and safety of ixabepilone, a novel epothilone analogue
    Xavier Pivot
    Oncologie Médicale, Centre Hospitalier Universitaire, Besancon, France
    Clin Breast Cancer 7:543-9. 2007
    ..Phase II clinical studies have demonstrated high activity in patients with taxane-resistant metastatic breast cancer and in patients with other chemotherapy-resistant tumor types...
  40. ncbi request reprint Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding
    Bernard Royer
    Laboratoire de Pharmacologie Clinique, CHU Jean Minjoz, Besancon, France
    Anticancer Drugs 16:1009-16. 2005
    ..p. bath containing 50 mg/m cisplatin for 2 h. A new protocol with a renewed bath and a higher cisplatin concentration is under investigation...
  41. ncbi request reprint Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by Xavier Pivot
    Xavier Pivot
    Medical Oncology University Hospital, Besancon, INSERM U645, France
    Drugs 67:1800-1. 2007
  42. doi request reprint Predictors of re-excision for positive or close margins in breast-conservation therapy for pT1 tumors
    Rajeev Ramanah
    Breast Care Unit, Department of Gynaecologic Surgery, Besancon University Hospital, Besancon, France
    Am J Surg 195:770-4. 2008
    ..Because breast-conservation therapy (BCT) is the standard treatment, the aim of our study was to determine factors predisposing patients to re-excision for pT1 tumors...
  43. ncbi request reprint Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma
    Xavier Pivot
    CHU J Minjoz, Besancon, France
    Am J Clin Oncol 25:561-4. 2002
    ..2%), and 19 had progressive disease (70.5%). The median overall survival from study inclusion was 8 months. This study suggests the association paclitaxel-epirubicin does not increase the known activity of anthracycline in recurrent STS...
  44. ncbi request reprint Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity
    Jean René Pallandre
    Institut National de la Santé et de la Recherche Médicale U645, EFS Bourgogne Franche Comte, University of Franche Comte, Besancon, France
    J Immunol 179:7593-604. 2007
    ..STAT3 modulation should be taken into account when assessing how regulatory T cells contribute to inflammatory diseases and tumor immunosurveillance...